Does molecular monitoring matter in early-stage breast cancer?

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. dhaber@mgh.harvard.edu.

Comment

Tilak K Sundaresan et al. Sci Transl Med. 2015.

. 2015 Aug 26;7(302):302fs35.

doi: 10.1126/scitranslmed.aac9445.

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. dhaber@mgh.harvard.edu.

Abstract

Serial monitoring of circulating tumor DNA predicts recurrence after treatment for localized breast cancer (Garcia-Murillas et al., this issue).

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Garcia-Murillas I, et al. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021. Sci Transl Med. 2015. PMID: 26311728